278 related articles for article (PubMed ID: 27235344)
1. Screening for anti-titin antibodies in patients with various paraneoplastic neurological syndromes.
Berger B; Stich O; Labeit S; Rauer S
J Neuroimmunol; 2016 Jun; 295-296():18-20. PubMed ID: 27235344
[TBL] [Abstract][Full Text] [Related]
2. "Non-classical" paraneoplastic neurological syndromes associated with well-characterized antineuronal antibodies as compared to "classical" syndromes - More frequent than expected.
Berger B; Bischler P; Dersch R; Hottenrott T; Rauer S; Stich O
J Neurol Sci; 2015 May; 352(1-2):58-61. PubMed ID: 25824848
[TBL] [Abstract][Full Text] [Related]
3. Paraneoplastic neurological syndromes with onconeural antibodies: A single center retrospective study.
Oliveira V; Videira G; Samões R; Carneiro P; Neves E; Santos E
J Neurol Sci; 2020 Nov; 418():117103. PubMed ID: 32877801
[TBL] [Abstract][Full Text] [Related]
4. SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes.
Stich O; Klages E; Bischler P; Jarius S; Rasiah C; Voltz R; Rauer S
Acta Neurol Scand; 2012 May; 125(5):326-31. PubMed ID: 21751968
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes.
Storstein A; Raspotnig M; Vitaliani R; Giometto B; Graus F; Grisold W; Honnorat J; Vedeler CA
J Neurol; 2016 May; 263(5):1001-1007. PubMed ID: 27007485
[TBL] [Abstract][Full Text] [Related]
6. A large screen for paraneoplastic neurological autoantibodies; diagnosis and predictive values.
Seluk L; Taliansky A; Yonath H; Gilburd B; Amital H; Shoenfeld Y; Kivity S
Clin Immunol; 2019 Feb; 199():29-36. PubMed ID: 30543927
[TBL] [Abstract][Full Text] [Related]
7. Screening for onconeural antibodies in neuromyelitis optica spectrum disorders.
Berger B; Hottenrott T; Rauer S; Stich O
BMC Neurol; 2017 Jan; 17(1):5. PubMed ID: 28068933
[TBL] [Abstract][Full Text] [Related]
8. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies.
Honnorat J; Cartalat-Carel S; Ricard D; Camdessanche JP; Carpentier AF; Rogemond V; Chapuis F; Aguera M; Decullier E; Duchemin AM; Graus F; Antoine JC
J Neurol Neurosurg Psychiatry; 2009 Apr; 80(4):412-6. PubMed ID: 18931014
[TBL] [Abstract][Full Text] [Related]
9. A single center retrospective study of paraneoplastic neurological syndromes with positive onconeural antibodies.
Fu P; He L; Tang N; Nie Q; Li Z
J Clin Neurosci; 2021 Jul; 89():336-342. PubMed ID: 34119290
[TBL] [Abstract][Full Text] [Related]
10. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer.
Rojas-Marcos I; Rousseau A; Keime-Guibert F; Reñé R; Cartalat-Carel S; Delattre JY; Graus F
Medicine (Baltimore); 2003 May; 82(3):216-23. PubMed ID: 12792307
[TBL] [Abstract][Full Text] [Related]
11. Onconeural antibodies in sera from patients with various types of tumours.
Monstad SE; Knudsen A; Salvesen HB; Aarseth JH; Vedeler CA
Cancer Immunol Immunother; 2009 Nov; 58(11):1795-800. PubMed ID: 19294382
[TBL] [Abstract][Full Text] [Related]
12. Screening for well-characterized paraneoplastic antineuronal antibodies in multiple sclerosis.
Stich O; Murek C; Rasiah C; Rauer S
Int J Neurosci; 2011 Aug; 121(8):477-9. PubMed ID: 21663382
[TBL] [Abstract][Full Text] [Related]
13. Parkinsonism and dysautonomia with anti-CV2/CRMP5 associated paraneoplastic neurological syndromes mimicking multiple system atrophy: a case report.
Song J; Zhang Y; Lang Y; Wang YH; Shao J; Cui L
BMC Neurol; 2021 Oct; 21(1):408. PubMed ID: 34702214
[TBL] [Abstract][Full Text] [Related]
14. Multiplex serology of paraneoplastic antineuronal antibodies.
Maat P; Brouwer E; Hulsenboom E; VanDuijn M; Schreurs MW; Hooijkaas H; Smitt PA
J Immunol Methods; 2013 May; 391(1-2):125-32. PubMed ID: 23500780
[TBL] [Abstract][Full Text] [Related]
15. Absent well-characterized onconeural antibodies in 283 patients with various polyneuropathies: A retrospective monocenter study.
Berger B; Klingler AJ; Rauer S; Stich O
J Neurol Sci; 2020 Jun; 413():116804. PubMed ID: 32240853
[TBL] [Abstract][Full Text] [Related]
16. Onconeural antibodies in patients with neurological symptoms: detection and clinical significance.
Raspotnig M; Vedeler CA; Storstein A
Acta Neurol Scand Suppl; 2011; (191):83-8. PubMed ID: 21711262
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
Younes-Mhenni S; Janier MF; Cinotti L; Antoine JC; Tronc F; Cottin V; Ternamian PJ; Trouillas P; Honnorat J
Brain; 2004 Oct; 127(Pt 10):2331-8. PubMed ID: 15361417
[TBL] [Abstract][Full Text] [Related]
18. Paraneoplastic Myeloneuropathies: Clinical, Oncologic, and Serologic Accompaniments.
Shah S; Vazquez Do Campo R; Kumar N; McKeon A; Flanagan EP; Klein C; Pittock SJ; Dubey D
Neurology; 2021 Jan; 96(4):e632-e639. PubMed ID: 33208548
[TBL] [Abstract][Full Text] [Related]
19. [Neurological syndromes, encephalitis].
Yamamoto T; Tsuji S
Gan To Kagaku Ryoho; 2010 Jun; 37(6):995-1005. PubMed ID: 20567100
[TBL] [Abstract][Full Text] [Related]
20. [Paraneoplastic peripheral neuropathies].
Antoine JC;
Rev Neurol (Paris); 2008 Dec; 164(12):1068-72. PubMed ID: 18848341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
